Fig. 1From: Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparibTreatment schedules in the NSCLC, breast cancer and HNSCC trials. Cisplatin is only given to patients in the CCRT arm. Radiotherapy in the HNSCC trial is delivered in five to six fractions per week in six weeks, the sixth fraction will be given on a weekday with an interval of at least six hours [61]Back to article page